In approximately the year 2000, the results of a number of important studies of non-small-cell lung cancer (NSCLC) were published.
factors.
CONCLUSIONS. In and after the year 2000, chemotherapy regimens changed greatly and survival of elderly patients significantly improved in our institute, and this improvement appears to be attributable mostly to the effect of salvage chemotherapy.
These results suggest that even elderly patients should be offered salvage chemotherapy regardless of age, if possible.
INTRODUCTION
Lung cancer is the leading cause of cancer-related death in many industrialized countries. Non-small cell lung cancer (NSCLC) accounts for approximately 80% to 85% of all lung cancers, and the majority of patients have metastatic disease at the time of diagnosis 1 . Previous data indicate that more than 50% of advanced NSCLC are diagnosed in patients aged ≥65 years and about 30% to 40% are diagnosed in patients ≥70 years of age 2 . NSCLC can therefore be regarded as a disease of the elderly, and the proportion of older adults among NSCLC patients is expected to progressively increase due to the aging of the populations of most developed countries.
Platinum-based combination chemotherapy improves survival and quality-of-life (QOL) in patients with advanced NSCLC, and is now widely accepted as the standard in chemotherapy 3, 4 . However, platinum-based chemotherapy is often contraindicated in elderly patients because of patient deficits in functional status and organ function. In addition, elderly patients have approximately twice as many comorbidities as the general population 5, 6 . Past studies on the effect of age on treatment choices for advanced NSCLC have revealed that elderly patients were less likely to receive active treatments 7-9 . Until recently, clinical trials for NSCLC have not specifically examined the importance of chronological age or the desirability of an upper age limit for treatment. Indeed, it has been reported that elderly patients are under-represented in those trials. In fact, according to a survey conducted by the Southwest Oncology Group, only 39% of patients enrolled in lung cancer trials between 1993 and 1996 were older than age 65, even though such patients represent 66% of the overall cancer patient population 10 .
The lack of clinical data on elderly NSCLC patients encouraged physicians to carry out elderly-specific clinical trials. In the 1990s, third-generation cytotoxic agents, such as vinorelbine (VNR), gemcitabine, docetaxel (DOC), paclitaxel, and irinotecan, were developed, and single-agent chemotherapy regimens using these agents were investigated in many phase II trials. In 1999, the results of the first elderly-specific phase III trial comparing VNR to best supportive care were published 11 . In that study, a significant survival benefit was seen in patients receiving VNR. Furthermore, VNR was well tolerated and QOL scores were better in patients treated with VNR. Then, in 2000, 2 phase III trials revealed a survival benefit for DOC when used as second-line chemotherapy agent, which was the first evidence for the effectiveness of second-line chemotherapy for NSCLC 12, 13 .
In addition, in 2002, as compared to other countries, approval for gefitinib, epidermal growth factor tyrosine kinase inhibitor (EGFR-TKI), was granted early in Japan.
These results should have a significant impact on clinical practice relating to advanced NSCLC in the elderly. In this study, we reviewed data on chemotherapy regimens used in the treatment of elderly NSCLC patients at our institute, and compared regimens and patient outcomes before and after year 2000.
MATERIALS AND METHODS

Patients
Between July 1992 and December 2003, 223 NSCLC patients aged ≥70 years received chemotherapy alone as their initial treatment at the National Cancer Center Hospital
East. These patients were divided into 2 groups: those that began treatment between 1992 and 1999 (group A) and those that began treatment between 2000 and 2003 (group B). Chemotherapy regimens and outcomes were then compared between groups.
Group B patients were then subdivided into 2 groups-the platinum-based chemotherapy group and the non-platinum-based chemotherapy group-and the clinical factors responsible for treatment choice were then analyzed. In addition, Group B patients were subdivided into another two groups; EGFR-TKI treated group or not-treated group. All patient data were obtained from our database.
Tumor evaluation and statistical analysis
Survival time was measured from the start of chemotherapy to either the time of death from any cause or the date patients were last known to be alive. The survival curve was estimated using the Kaplan-Meier method, and compared by using the log-rank test.
Comparisons between individual clinical factors were performed using the χ 2 test.
Multivariate analysis was conducted according to the Cox proportional hazards model.
P<0.05 was considered to denote statistical significance. All statistical analyses were performed using StatView, Version 5.0 (Abacus Concepts, Berkley, CA).
RESULTS
Patient characteristics
Patient characteristics are listed in Table 1 . There were 74 patients in group A and 149 in group B. Median age was almost identical, but the proportion of patients aged ≥75
years was significantly higher in group B (p = 0.0182). Other clinical factors, including sex, performance status (PS), tumor histology, disease stage, and smoking history, were not significantly different between the groups.
First-line chemotherapy
Details of first-line chemotherapy are shown in Table 2 . In group A, 83% of patients received platinum-based chemotherapy; two-thirds of these were platinum-based plus second-generation combination chemotherapy regimens. In group B by contrast, although 55% of patients received platinum-based chemotherapy, 41% received non-platinum-based chemotherapy and 4% received epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). EGFR-TKI as first-line treatment was all clinical trial settings. In group B, second-generation agents were no longer used, and the most frequently administered third-generation single-agent chemotherapy was VNR.
Clinical factors influencing selection of platinum-based and non-platinum-based chemotherapy
In group B, 143 patients (96%) received platinum-based or non-platinum-based chemotherapy; only 6 patients (4%) received EGFR-TKI. In order to determine the clinical factors that affected the selection of platinum-based and non-platinum-based chemotherapy, relevant clinical factors were individually compared between these 2 patient subgroups. As shown in Table 3 , only PS significantly differed between groups: patients with a PS of 0 or 1 tended to receive platinum-based chemotherapy;
those with a PS of 2 tended to receive non-platinum-based chemotherapy (p = 0.004).
Other clinical factors did not significantly differ between the groups; however, the proportion of patients aged ≥75 years was marginally higher in the non-platinum-based chemotherapy group (p = 0.0596).
EGFR-TKI treatment
In group B, 34 patients received EGFR-TKI treatment during entire treatment period, while no patients in group A. In group B, the proportion of patients who received EGFR-TKI was significantly higher in female, adenocarcinoma, and never-smoked patients (Table 4) .
Second-line chemotherapy and beyond
The characteristics of patients who underwent multiple-line chemotherapy are shown in Table 5 . In group A, second-line chemotherapy was administered to only 4 patients (5%) and no patients underwent third-line chemotherapy. In group B by contrast, second-line and third-line chemotherapy was administered to 62 (42%) and 22 (15%) patients, respectively. DOC was the agent most frequently used in second-line chemotherapy; EGFR-TKI was the most common agent for third-line chemotherapy.
Survival
Median survival time (MST) was 6.7 months in group A and 8.1 months in group B (p = 0.0109). The 1-year-survival rate and 2-year-survival rate were 14% and 7%, respectively, in group A, and 35% and 20% in group B. Survival curves are shown in Figure 1 . The relationships between clinical variables and survival are shown in Table   6 . Univariate analysis revealed that female, stage ≤IIIB, never-smoker, EGFR-TKI treatment, and the administration of salvage chemotherapy were associated with better survival. However, multivariate analysis demonstrated that only clinical stage and the administration of salvage chemotherapy were independent prognostic factors. As we anticipated, the proportion of patients who received non-platinum-based chemotherapy, with either 1 or 2 agents, was higher in group B; however, more than 50% of patients in group B still received platinum-based chemotherapy. We further investigated group B to determine what clinical factors were associated with the selection of platinum-based or non-platinum-based chemotherapy. The results were unsurprising: patients with a PS of 2 aged ≥75 tended to receive non-platinum-based chemotherapy. Several sub-group analyses from phase III trials indicated that, when PS was not impaired, platinum-based chemotherapy was equally safe and effective in patients aged over and under 70 years [14] [15] [16] [17] . The first elderly-specific trial comparing platinum-based and non-platinum-based chemotherapy regimens also indicated that patients aged 70 to 74 years might derive more benefit from platinum-based chemotherapy than from non-platinum -based chemotherapy 18 . However, it is unclear whether platinum-based chemotherapy is safe and effective for patients aged ≥75 years.
DISCUSSION
In the present study, the proportion of patients who received salvage chemotherapy was also higher in group B. In conclusion, in our institute, chemotherapy regimens changed considerably after 
